Travere Therapeutics (TVTX) closed at $52.04 on November 11, 2026, up 0.1% from the previous close, on volume of 713,361 shares (30-day average 2,283,538).
Data as of November 11, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 19, 2026 | Diagonal Put Spread | 15-Jan-27 : 21-Jan-2850 : 47.5 P | 1,508 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
Travere Therapeutics (TVTX) Receives a Buy from J.P. Morgan
TipRanks (Fri, 6-Nov 9:58 AM ET)
Travere Therapeutics to Participate at Upcoming Investor Conferences
Business Wire (Tue, 3-Nov 4:30 PM ET)
Travere Therapeutics Reports Third Quarter 2026 Financial Results
Business Wire (Mon, 2-Nov 4:01 PM ET)
Travere Therapeutics to Report Third Quarter 2026 Financial Results
Business Wire (Mon, 26-Oct 4:30 PM ET)
Business Wire (Fri, 23-Oct 7:20 PM ET)
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Mon, 12-Oct 5:00 PM ET)
Business Wire (Fri, 2-Oct 10:00 AM ET)
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm
PRNewswire (Wed, 30-Sep 9:58 AM ET)
Business Wire (Wed, 23-Sep 7:00 AM ET)
Travere Therapeutics Announces Planned Chief Executive Officer Transition
Business Wire (Mon, 21-Sep 4:05 PM ET)
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
Travere Therapeutics trades on the NASDAQ stock market under the symbol TVTX.
As of November 11, 2026, TVTX stock price climbed to $52.04 with 713,361 million shares trading.
TVTX has a beta of 1.72, meaning it tends to be more sensitive to market movements. TVTX has a correlation of 0.14 to the broad based SPY ETF.
TVTX has a market cap of $4.84 billion. This is considered a Mid Cap stock.
Last quarter Travere Therapeutics reported $225 million in Revenue and -$.31 earnings per share. This beat revenue expectation by $30 million and missed earnings estimates by -$.59.
In the last 3 years, TVTX traded as high as $68.73 and as low as $5.12.
The top ETF exchange traded funds that TVTX belongs to (by Net Assets): VTI, IWM, XBI, VXF, VB.
TVTX has outperformed the market in the last year with a price return of +51.4% while the SPY ETF gained +12.6%. However, in the short term, TVTX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -14.5% vs -1.5% return in SPY. But in the last 2 weeks, TVTX shares have fared better than the market returning +2.3% compared to SPY -1.3%.
TVTX support price is $50.27 and resistance is $53.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TVTX shares will trade within this expected range on the day.
